The earnings call reflected significant financial and operational challenges with revenue shortfalls, unexpected market performance, and inventory issues. While there are promising R&D developments, these are long-term. Immediate financial pressures and market challenges dominate the current outlook.
Company Guidance
During the investor presentation call for Futura Medical plc, Interim CEO Alex Duggan provided guidance indicating that the company's full-year 2025 performance is expected to fall significantly below market expectations due to challenges in sustaining consumer uptake and lower-than-anticipated repeat sales. Despite launching in seven countries in H1, the initial strong trials did not translate into continued sales, affecting supply volumes and royalty streams. Angela Hildreth reported a revenue of just over GBP 1 million for the first half of 2025, with a gross profit of GBP 0.7 million, but also highlighted a GBP 0.49 million provision for inventory obsolescence. The company incurred an exceptional charge of GBP 3.6 million due to impairment of U.S. plant and equipment, contributing to a loss after tax of GBP 6.6 million. The adjusted loss after tax was GBP 1.9 million, with cash reserves at GBP 3.69 million at the period's end. Full-year sales for 2025 are now projected to be between GBP 1.3 million and GBP 1.4 million, with cash reserves reduced to GBP 2.7 million by the end of August. The company is actively exploring commercial and financing options to extend its cash runway, which currently runs into January 2026.
R&D Developments
Futura is advancing two new products: Project Intense and WSD4000. Project Intense aims to enhance sensorial effects for men, with regulatory approval expected by the end of 2025. WSD4000 targets women's sexual response, with significant market potential, though it is expected to launch in the latter half of 2028.
Cost Reductions
Core G&A costs were reduced from GBP 3.4 million to GBP 2.6 million, demonstrating successful cost management efforts.
Patent Advancements
Notable progress in patent coverage with expected notice of allowance in China and a continuation patent in the U.S. that should trigger a GBP 1.9 million milestone payment in 2026.
Futura Medical (GB:FUM) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:FUM Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Sep 30, 2025
3.84p
3.80p
-1.04%
Apr 15, 2025
8.95p
9.64p
+7.71%
Sep 10, 2024
40.00p
38.00p
-5.00%
Apr 10, 2024
42.80p
37.00p
-13.55%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Futura Medical PLC (GB:FUM) report earnings?
Futura Medical PLC (GB:FUM) is schdueled to report earning on Apr 15, 2026, TBA (Confirmed).
What is Futura Medical PLC (GB:FUM) earnings time?
Futura Medical PLC (GB:FUM) earnings time is at Apr 15, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.